4.7 Article

Low Hepatitis C Viral Load Predicts Better Long-Term Outcomes in Patients Undergoing Resection of Hepatocellular Carcinoma Irrespective of Serologic Eradication of Hepatitis C Virus

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 6, Pages 766-773

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2012.44.3234

Keywords

-

Categories

Funding

  1. Health and Labor Sciences Research Grant for Clinical Cancer Research [H21-015]
  2. Japanese Foundation for Multidisciplinary Treatment of Cancer
  3. Bayer
  4. Dainippon Sumitomo

Ask authors/readers for more resources

Purpose Hepatitis C virus (HCV) infection has been recognized as a potent risk factor for the postoperative recurrence of hepatocellular carcinoma (HCC). However, little is known about the impact of HCV viral load on surgical outcomes. The study objective was to investigate clinical significance of HCV viral load on long-term outcomes of HCC. Patients and Methods Three hundred seventy patients who were classified as Child-Pugh class A and underwent curative liver resections for HCV-related HCC were divided into low and high viral load groups (<= or >5.3 log(10)IU/mL) based on the results of a minimum P value approach to predict moderate to severe activity of hepatitis; the clinical outcomes were then compared. Results The 5-year recurrence-free survival rate was 36.1% in the low viral load group and 12.4% in the high viral load group (P < .001). The 5-year overall survival rate was 76.6% in the low viral load group and 57.7% in the high viral load group (P < .001). Multivariate analysis confirmed significant correlation between high viral load and tumor recurrence with a hazard ratio of 1.87 (95% CI, 1.41 to 2.48; P < .001). Subanalysis revealed that the favorable results in the low viral load group were not attributed to whether or not serologic eradication of HCV was obtained both in primary and recurrent lesions. Conclusion Low HCV viral load predicts better long-term surgical outcomes in patients with HCC regardless of the serologic eradication of HCV. J Clin Oncol 31:766-773. (C) 2012 by American Society of Clinical Oncology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available